CRISPR Therapeutics (CRSP) has declined 23.6% in the year-to-date period compared with the industry’s 1.7% fall, as seen in the chart below. The stock also underperformed the sector and the S&P 500. The shares are also trading below its 50-day and 200-day moving averages.CRSP Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchSince the start of this year, CRSP received approval for its Vertex Pharmaceuticals (VRTX) -partnered one-shot gene therapy Casgevy in two blood diso ...